The Cardiovascular Impact of Carfilzomib in Multiple Myeloma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Luthi, Jennifer [1 ]
Belohlavek, Marek [1 ]
Mookadam, Farouk [1 ]
Mayo, Angela [1 ]
Fonseca, Rafael [1 ,2 ]
Bergsagel, P. Leif
Reeder, Craig B. [1 ]
Mikhael, Joseph R. [1 ]
Stewart, Keith [2 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Role of carfilzomib in the treatment of multiple myeloma
    Khan, Rashid Z.
    Badros, Ashraf
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (04) : 361 - 372
  • [12] Carfilzomib for relapsed or refractory multiple myeloma
    Tanimoto, Tetsuya
    Tsuda, Kenji
    Oshima, Kumi
    Mori, Jinichi
    Shimmura, Hiroaki
    LANCET ONCOLOGY, 2018, 19 (01): : E1 - E1
  • [13] Carfilzomib for relapsed or refractory multiple myeloma reply
    Dimopoulos, Meletios A.
    Kimball, Amy S.
    LANCET ONCOLOGY, 2018, 19 (01): : E2 - E2
  • [14] An overview of the role of carfilzomib in the treatment of multiple myeloma
    Ziogas, Dimitrios C.
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (17) : 1883 - 1897
  • [15] Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib
    Milan, Alberto
    Bruno, Giulia
    Maffei, Ilaria
    Iannaccone, Andrea
    Ravera, Agnese
    Schiavone, Domenica
    Veglio, Franco
    CURRENT HYPERTENSION REVIEWS, 2019, 15 (01) : 47 - 53
  • [16] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    DRUGS, 2012, 72 (15) : 2023 - 2032
  • [17] Carfilzomib in multiple myeloma: gold, silver, or bronze?
    Reece, Donna E.
    BLOOD, 2012, 120 (14) : 2776 - 2777
  • [18] Optimizing carfilzomib use in multiple myeloma treatment
    Yoon, Sung-Soo
    BLOOD RESEARCH, 2019, 54 (03) : 159 - 161
  • [19] Carfilzomib in multiple Myeloma Good Control of the cardiovascular Risk allows optimal Therapy with Proteasome Inhibitors
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (09) : 476 - 477
  • [20] The role of carfilzomib in relapsed/refractory multiple myeloma
    Yee, Andrew J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
12345